DEVELOPING ORAL BIOLOGICS THAT ACT ON CELLS IN THE SMALL INTESTINE WITH SYSTEMIC THERAPEUTIC EFFECTS

EVELO BIOSCIENCES REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - July 30, 2020
EVELO BIOSCIENCES TO PRESENT CLINICAL DATA FROM PHASE 1/2 TRIAL OF EDP1503 AT THE ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER VIRTUAL MEETING
Cambridge, MA - July 1, 2020
EVELO BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Cambridge, MA - June 24, 2020
EVELO BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Cambridge, MA - June 24, 2020

Cells in the small intestine play a central role in governing our immune, metabolic and neurological systems.

Our first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties.

Our therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.

Our Platform

We have developed an integrated platform to develop oral biologics which harness the central role that cells in the small intestine play in governing our immune, metabolic and neurological systems.
The efficiency of our platform has allowed us to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases and cancer.

Our Portfolio

We currently have four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. We are also advancing additional oral biologics through preclinical development in other disease areas.

About our portfolio

Evelo is led by a team with deep experience.

Our leadership team has founded, led, and grown transformative platform biotechnology companies. Our team has also developed and commercialized medicines that have impacted many lives.

About our team